- Home
- SPFI vs RLMD Comparison
SPFI vs RLMD Comparison
Compare SPFI & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SPFI | RLMD |
|---|---|---|
| Founded | 1941 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 794.2M | 661.9M |
| IPO Year | 2019 | 2012 |
Fundamental Metrics
Financial Performance| Metric | SPFI | RLMD |
|---|---|---|
| Price | $42.14 | $6.57 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $46.00 | $12.40 |
| AVG Volume (30 Days) | 104.8K | ★ 1.3M |
| Earning Date | 04-28-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.68% | N/A |
| EPS Growth | 17.81 | ★ 45.28 |
| EPS | ★ 0.85 | N/A |
| Revenue | N/A | ★ $13,070.00 |
| Revenue This Year | $22.65 | N/A |
| Revenue Next Year | $9.40 | N/A |
| P/E Ratio | $48.98 | ★ N/A |
| Revenue Growth | N/A | ★ 154.83 |
| 52 Week Low | $35.34 | $0.53 |
| 52 Week High | $45.09 | $8.00 |
Technical Indicators
Market Signals| Indicator | SPFI | RLMD |
|---|---|---|
| Relative Strength Index (RSI) | 57.45 | 47.02 |
| Support Level | $38.32 | $6.17 |
| Resistance Level | $42.10 | $7.46 |
| Average True Range (ATR) | 1.11 | 0.43 |
| MACD | 0.07 | 0.05 |
| Stochastic Oscillator | 83.73 | 61.15 |
Price Performance
Historical ComparisonAbout SPFI South Plains Financial Inc.
South Plains Financial Inc operates as a bank holding company. The company provides a wide range of commercial and consumer financial services to small and medium-sized businesses and individuals. The principal business activities include commercial and retail banking, along with insurance, investment, trust, and mortgage services. The company has one reportable segment: banking. The majority of the company's revenues is derived from interest income and other sources, including loans, securities and derivatives.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.